Home » Stocks » Metacrine

Metacrine, Inc. (MTCR)

Stock Price: $10.10 USD 0.05 (0.50%)
Updated Sep 18, 2020 4:00 PM EDT - Market closed
After-hours: $10.05 -0.05 (-0.50%) Sep 18, 7:31 PM

Stock Price Chart

Key Info

Market Cap 195.76M
Revenue (ttm) n/a
Net Income (ttm) -33.30M
Shares Out 19.38M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Sep 18, 2020
Last Price $10.10
Previous Close $10.05
Change ($) 0.05
Change (%) 0.50%
Day's Open 10.00
Day's Range 10.00 - 10.29
Day's Volume 219,456
52-Week Range 10.00 - 16.19

More Stats

Market Cap 195.76M
Enterprise Value 167.79M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.38M
Float 6.18M
EPS (basic) n/a
EPS (diluted) -1.28
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -33.30M
Free Cash Flow n/a
Net Cash 27.97M
Net Cash / Share 1.44
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit-1.45
Operating Income-30.00-26.73
Net Income-28.93-25.82
Shares Outstanding2.382.09
Earnings Per Share-12.17-12.35
Operating Cash Flow-27.75-25.48
Capital Expenditures-0.08-0.68
Free Cash Flow-27.83-26.16
Cash & Equivalents55.6572.99
Total Debt11.452.85
Net Cash / Debt44.2070.13
Book Value-78.24-51.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Metacrine, Inc.
Country United States
Employees 32
CEO Preston S. Klassen

Stock Information

Ticker Symbol MTCR
Stock Exchange NASDAQ
Sector Health Technology
Industry Biotechnology
Unique Identifier NASDAQ: MTCR
IPO Date September 16, 2020


Metacrine, Inc. is a clinical-stage biopharmaceutical company that engages in the discovery and development of differentiated therapies for patients with liver and gastrointestinal diseases. Its farnesoid X receptor, or FXR, is central to modulating liver and GI diseases. The company was founded by Ronald M. Evans, Richard A. Heyman, and Michael Downes in 2014 and is headquartered in San Diego, CA.